GenScript

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 235,000 customers from over 100+ countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript has over 6,000 employees globally, 33% holding master’s and Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 200 patents and about 800 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.